Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

Stock Information for Relmada Therapeutics Inc - Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.